Anterix Appoints New CFO, Grants Stock Awards

TL;DR

Anterix names new CFO, John Denning, with $400k salary + stock/options.

AI Summary

Anterix Inc. announced on March 27, 2024, the appointment of John M. Denning as Chief Financial Officer, effective April 1, 2024. Denning will receive an annual base salary of $400,000 and is eligible for a discretionary annual bonus. He will also be granted 150,000 restricted stock units, vesting over three years, and a stock option award for 100,000 shares, vesting over four years.

Why It Matters

The appointment of a new CFO and the associated stock and option grants signal a potential shift in financial leadership and a commitment to retaining key talent within Anterix Inc.

Risk Assessment

Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty regarding future financial strategy and performance.

Key Numbers

• $400,000 — CFO Base Salary (Annual compensation for John M. Denning)
• 150,000 — RSUs Granted (Stock awards to new CFO, vesting over 3 years)
• 100,000 — Stock Options Granted (Equity incentive for new CFO, vesting over 4 years)

Key Players & Entities

• Anterix Inc. (company) — Registrant
• John M. Denning (person) — Newly appointed Chief Financial Officer
• $400,000 (dollar_amount) — Annual base salary for new CFO
• 150,000 (dollar_amount) — Restricted stock units granted to new CFO
• 100,000 (dollar_amount) — Stock options granted to new CFO
• March 27, 2024 (date) — Date of the report
• April 1, 2024 (date) — Effective date for new CFO

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value ATEX The Nasdaq Stock Market
• $33.56 — " Common Stock "), at a strike price of $33.56 per share, the closing price of the Com

Filing Documents

• atex-20240327.htm (8-K) — 32KB
• 0001304492-24-000039.txt ( ) — 157KB
• atex-20240327.xsd (EX-101.SCH) — 2KB
• atex-20240327_lab.xml (EX-101.LAB) — 22KB
• atex-20240327_pre.xml (EX-101.PRE) — 13KB
• atex-20240327_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements Certain statements contained in this Current Report on Form 8-K constitute forward-looking statements within the meaning of the federal securities laws that involve risks and uncertainties. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future events such as statements in this Current Report on Form 8-K related to the ability of the Company to achieve stockholder approval of additional shares of Common Stock and the exercisability of the Stock Options. Forward-looking statements speak only as of the date they are made and readers are cautioned not to put undue reliance on such statements, as they are subject to a number of risks and uncertainties. Actual events or results may differ materially from those contemplated in this Current Report on Form 8-K. The Company's filings with the Securities and Exchange Commission (" SEC "), which you may obtain for free at the SEC's website at http://www.sec.gov, discuss some of the important risk factors. The Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Anterix Inc. Dat e: April 2, 2024 /s/ Gena L. Ashe Gena L. Ashe Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR